A new study led by Mass General Brigham investigators compared the effects of repeated intravenous (IV) ketamine and intranasal (IN) esketamine in patients with treatment-resistant depression. In a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback